This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidneydisease (CKD) and elevated levels of various biomarkers. in the NUA group.
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF). Additional ACC.25
Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD. Understanding and addressing the dysregulated immune system is a promising approach to modifying cardiorenal outcomes in people with CKD.
This study aimed to identify predictors of worse clinical outcome after deferral of non-emergency cardiovascular interventions. to 5.12; p=0.049), chronic kidneydisease (HR 1.89; 95% CI 1.03 to 3.49; p=0.041) as well as severe valvular heart disease (HR 3.08; 95% CI 1.68 Arterial hypertension (HR 2.27; 95% CI 1.00
A mixed model repeated measurements model (MMRM) was used to evaluate the effect of empagliflozin vs. placebo on the analysed biomarkers. On the other hand, PRO-C3, C1M, and C3M were not associated with worse HF severity or study outcomes.
Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidneydisease. The future of care demands a holistic approach.
This blog post explores the development of such partnerships and their potential to transform healthcare outcomes. Engaging individuals as active participants in their care plans can significantly enhance outcomes and improve overall quality of life. Key contributions: Advanced cardiac imaging (e.g.,
Abstract Aims Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidneydisease. Albuminuria is common in heart failure and associated with worse outcomes, but its prevalence and relationship to outcome in ATTR-CA remains unclear.
This improves diagnostic accuracy and ultimately leads to better patient outcomes. Artificial Intelligence Artificial intelligence (AI) has revolutionized cardiac diagnosis by allowing for the analysis of extensive patient data to identify patterns and predict outcomes.
Measuring eGFR and albuminuria is recommended for assessing kidneydisease in all hypertensive patients. Philip Moons (Belgium) presented the first results showing that patient-reported outcomes (PROs) vary significantly across different heart defects, and anatomical complexity is a poor predictor of PROs. Watch here!
5 Over my career as a cardiovascular surgeon, as well as an immunologist, I have witnessed how current treatments for ASCVD have led to considerable improvements in outcomes, yet many patients remain vulnerable to life-threatening cardiac events.1,6 34 The safety of colchicine, 0.5 μ/L on 0.6 N Engl J Med. 2019;381(26):2497-2505.
Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH. In this study, we examined the relationship between ICH and CKD, as well as intracranial arterial calcification (IAC) as an intermediate biomarker.
Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025.
With the holiday season approaching and fall in full swing, it’s the perfect time to reaffirm our commitment to delivering excellent care, improving patient outcomes, and making the most of every available resource. cardiometabolic health CME/CE conference: the 19th Annual CMHC. In the U.S.,
Background Acute kidney injury (AKI) in the context of acute decompensated heart failure (ADHF) encompasses a broad spectrum of phenotypes with associated disparate outcomes. AKI was defined using KidneyDisease Improving Global Outcomes (KDIGO) AKI criteria.
Both reperfusion, as judged by the biomarker curve, and patency, as assessed by the angiogram, were correlated with the rapidity and depth of T wave inversion. The only other processes identified that caused this type of postinfarction T wave evolution were cardiopulmonary resuscitation, reinfarction, and very small infarcts.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content